Modality
Bispecific Ab
MOA
TROP-2 ADC
Target
USP1
Pathway
Epigenetic
CRCFL
Development Pipeline
Preclinical
~Jan 2020
→ ~Apr 2021
Phase 1
Jul 2021
→ Nov 2031
Phase 1Current
NCT05135964
1,988 pts·CRC
2025-04→2031-11·Active
NCT07684130
1,853 pts·CRC
2021-07→2025-04·Completed
3,841 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-04-2211mo agoInterim· CRC
2031-11-155.6y awayInterim· CRC
Trial Timeline
Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
P1
Complet…
P1
Active
Catalysts
Interim
2025-04-22 · 11mo ago
CRC
Interim
2031-11-15 · 5.6y away
CRC
ActiveCompleted|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05135964 | Phase 1 | CRC | Active | 1988 | Safety |
| NCT07684130 | Phase 1 | CRC | Completed | 1853 | MRD |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| ABB-2476 | AbbVie | Phase 1/2 | USP1 | |
| BAY-6520 | Bayer | Phase 2 | AHR | |
| Bemazumab | Regeneron | Phase 1 | VEGF | |
| GMA-5010 | Genmab | Phase 3 | JAK2 | |
| INC-1582 | Incyte | Phase 1/2 | APOC3 | |
| Surarasimod | Xenon Pharma | Phase 2 | SHP2 | |
| Lisonesiran | Arvinas | Phase 1/2 | PARP | |
| Zoriosocimab | Akero | Approved | C5 | |
| Tezesotorasib | Enliven | Phase 2 | USP1 | |
| ETN-5063 | 89bio | Phase 1/2 | USP1 |